Blood samples are needed for important research on

genetic disorders including microdeletion/duplications. Who is eligible?

• Women and their partners (presumed biological father of the fetus) who are currently pregnant and carrying a fetus that has been diagnosed with a microdeletion/duplication syndrome or another genetic disorder (positive karyotype result or positive result on microarray test).

What is the purpose of the study?

The goal of this study is to develop a non-invasive prenatal blood test that can diagnose genetic disorders in the fetus by looking at fetal DNA (genetic material) found in the mother's bloodstream during pregnancy.

Women carrying a fetus diagnosed with microdeletions/microduplications (small missing or extra pieces of DNA that can cause problems) or other genetic disorders will be asked to participate.

If this study is successful, it will reduce the need for invasive procedures during pregnancy such as amniocentesis and chorionic villus sampling (CVS) but still enable women to find out accurate information regarding their baby's health early in the pregnancy.

What does participation require?

The mother and biological father (if available) will be asked to provide a blood sample. There will be 4 tubes collected from the mother (approximately 3 tablespoons) and 1 tube collected from the father (2 teaspoons). The samples will be collected at no cost to the couple.

Neither subjects nor their doctor will receive any results from the study. Therefore, there is no direct benefit from participating. This study and the subjects who participate may help other women in the future if the study results in a new test available to pregnant women.

Each couple will receive \$100 for their participation.

Call research at Natera at 877-476-4743 X 446 or email <u>research@natera.com</u> if interested

This study is sponsored and conducted by Natera, Inc. All patient samples and information will be treated in full compliance with HIPAA privacy laws.